---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012630"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:21:51.362880+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports partial response in Decoy20 monotherapy; raises $5.7M

## Summary
- Decoy20 monotherapy induced partial response (liver metastases reduction) in one urothelial cancer patient; later disease progression.
- 7 patients dosed in combination with tislelizumab; first 3 evaluable: 1 stable disease, 2 progression.
- Raised $5.7M gross proceeds from convertible notes converted to common stock and pre-funded warrants in July 2025.
- Monotherapy portion completed; initial combination safety cohort dosing ongoing, with initial data expected later in 2025.

## SEC filing metadata
- accession: 0001493152-25-012630
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315225012630/0001493152-25-012630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315225012630/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012630
- JSON: https://secwatch.observer/filing/0001493152-25-012630.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.